Soluble CD30 for the prediction and detection of kidney transplant rejection

Drug News and Perspectives

Volumn 22, Issue 7, 2009, Pages 409-413

  Arjona, Alvaro ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD30 ANTIGEN; HLA ANTIBODY; PANEL REACTIVE ANTIBODY; TACROLIMUS;

ACUTE GRAFT REJECTION; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; PREDICTION; PROTEIN BLOOD LEVEL; REVIEW;

ANTIGENS, CD30; BIOLOGICAL MARKERS; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 72449184822     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2009.22.7.1401356     Document Type: Review

References (32)

1. Susal, C., Pelzl, S., Simon, T. and Opelz, G. Advances in pre- and posttransplant immunologic testing in kidney transplantation. Transplant Proc 2004, 36(1): 29-34. (Pubitemid 38177180)
2. Truong, D.Q., Darwish, A.A., Gras, J. et al. Immunological monitoring after organ transplantation: potential role of soluble CD30 blood level measurement. Transpl Immunol 2007, 17(4): 283-287 (Pubitemid 46687027)
3. Cinti, P., Pretagostini, R., Arpino, A. et al. Evaluation of pretransplont immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation 2005, 79(5): 599-601. (Pubitemid 40664014)
4. Fabrega, E., Unzueta, M.G., Cobo, M., Casafont, F., Amado, J.A. and Romero, F.P. Value of soluble CD30 in liver transplantation. Transplant Proc 2007, 39(7): 2295-2296 (Pubitemid 47418146)
5. Martinez, O.M., Villanueva, J., Abtahi, S., Beatty, P.R., Esquivel, C.O. and Krams, S.M. CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation 1998, 65(9): 1240-1247 (Pubitemid 28224344)
6. Manetti, R., Annunziato, F., Biagiotti, R. et al. CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human Immunodeficiency virus infection. J Exp Med 1994, 180(6): 2407-2411 (Pubitemid 24983550)
7. Pellegrini, P., Berghella, A.M., Contasta, I. and Adorno, D. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol 2003, 12(1): 49-61.
8. Romagnani, S., Del Prete, G., Maggi, E., Chilosi, M., Caligaris-Cappio, F. and Pizzolo, G. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol 1995, 57(5): 726-730
9. Kennedy, M.K., Willis, C.R. and Armitage, R.J. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 2006, 118(2): 143-152
10. Pelzl, S., Opelz, G., Wiesel, M. et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002, 73(1): 3-6. (Pubitemid 34094677)
11. Susal, C., Pelzl, S., Dohler, B. and Opelz, G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002, 13(6): 1650-1656 (Pubitemid 34579254)
12. Pelzl, S., Opelz, G., Daniel, V., Wiesel, M. and Susal, C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003, 75(3): 421-423 (Pubitemid 36222975)
13. Slavcev, A., Lacha, J., Honsova, E. et al. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection. Transpl Immunol 2005, 14(2): 117-121 (Pubitemid 40791127)
14. Susal, C., Pelzl, S. and Opelz, G. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation 2003, 76(8): 1231-1232 (Pubitemid 37339650)
15. Rodriguez, L.M., Paris, S.C., Arbelaez, M. et al. Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss. Hum Immunol 2007, 68(8): 652-60. (Pubitemid 47126660)
16. Langan, L.L., Park, L.P., Hughes, T.L. et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007, 7(4): 847-856 (Pubitemid 46481183)
17. Weimer, R., Susal, C., Yildiz, S. et al. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil. Transplant Proc 2005, 37(4): 1776-1778 (Pubitemid 40790828)
18. Sengul, S., Keven, K., Gormez, U., Kutlay, S., Erturk, S. and Erbay, B. Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation. Transplantation 2006, 81(8): 1216-1219 (Pubitemid 43754676)
19. Ayed, K., Abdallah, T.B., Bardi, R., Abderrahim, E. and Kheder, A. Plasma levels of soluble CD30 in kidney graft recipients as predictors of acute allograft rejection. Transplant Proc 2006, 38(7): 2300-2302 (Pubitemid 46068547)
20. Dong, W., Shunliang, Y., Weizhen, W. et al. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30. Transpl Immunol 2006, 16(1): 41-45
21. Wang, D., Wu, G.J., Wu, W.Z. et al. Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection. Transpl Immunol 2007, 17(4): 278-82. (Pubitemid 46687030)
22. Vaidya, S., Partlow, D., Barnes, T. and Gugliuzza, K. Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies. Transplantation 2006, 82(12): 1606-1609 (Pubitemid 46035636)
23. Vaidya, S., Partlow, D., Barnes, T., Thomas, P. and Gugliuzza, K. Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies. Clin Transplant 2006, 20(4): 461-464 (Pubitemid 43983824)
24. Kim, M.S., Kim, H.J., Kim, S.I. et al. Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation. Transplantation 2006, 82(12): 1602-1605
25. Yang, J.L., Hao, H.J., Zhang, B., Liu, Y.X., Chen, S. and Na, Y.Q. Level of soluble CD30 after kidney transplantation correlates with acute rejection episodes. Transplant Proc 2008, 40(10): 3381-3383
26. Kovac, J., Arnol, M., Vidan-Jeras, B., Bren, A.F. and Kandus, A. Does pretransplant soluble CD30 serum concentration affect deceased-donor kidney graft function 3 years after transplantation? Transplant Proc 2008, 40(5): 1357-1361
27. Slavcev, A., Honsova, E., Lodererova, A. et al. Soluble CD30 in patients with antibody-medi- ated rejection of the kidney allograft. Transpl Immunol 2007, 18(1): 22-27 (Pubitemid 46920972)
28. Platt, R.E., Wu, K.S., Poole, K., Newstead, C.G. and Clark, B. Soluble CD30 as a prognostic factor for outcome following renal transplantation. J Clin Pathol 2009, 62(7): 662-663
29. Altermann, W., Schlaf, G., Rothhoff, A. and Seliger, B. High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection? Nephrol Dial Transplant 2007, 22(10): 2795-2799
30. Kim, K.H., Oh, E.J., Jung, E.S. et al. Evaluation of pre- and posttransplantation serum interfer-on-gomma and soluble CD30 for predicting liver allograft rejection. Transplant Proc 2006, 38(5): 1429-1431
31. Frisaldi, E., Conca, R., Magistroni, P. et al. Prognostic values of soluble CD30 and CD30 gene polymorphisms in heart transplantation. Transplantation 2006, 81(8): 1153-1156 (Pubitemid 43754666)
32. Saini, D., Ramachandran, S., Nataraju, A. et al. Activated effector and memory T cells contribute to circulating sCD30: potential marker for islet allograft rejection. Am J Transplant 2008, 8(9): 1798-1808